Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TP-0184 (Itacnosertib) for Anemia in Low/Intermediate Risk MDS
NCT04623996Phase 2Terminated
- Sponsor
- Sumitomo Pharma America
- Start
- Dec 2020
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of itacnosertib in anemia and myelodysplastic syndrome (MDS), sponsored by Sumitomo Pharma America. Primary endpoints: Incidence of Dose Limiting Toxicities at 28 days, Number of Participants With Adverse Events and Serious Adverse Events up to 4 months and 1 more. Started Dec 2020; status: terminated.
02
Drugs
itacnosertib
03
Conditions
anemiamyelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT04623996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04623996.